• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.

作者信息

Kopmar Noam E, Gooley Ted, Curley Niall, Russell Kathryn, Shaw Carole, Schonhoff Kelda, Lim John, Halpern Anna B, Walter Roland B, Scott Bart L, Appelbaum Jacob, Hendrie Paul C, Estey Elihu H, Percival Mary-Elizabeth M

机构信息

Department of Medicine, University of Washington, Seattle, WA, USA.

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

出版信息

Leuk Lymphoma. 2023 May;64(5):1057-1059. doi: 10.1080/10428194.2023.2185087. Epub 2023 Mar 9.

DOI:10.1080/10428194.2023.2185087
PMID:36896478
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10330652/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d00/10330652/88bb2cf4fc1f/nihms-1900060-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d00/10330652/88bb2cf4fc1f/nihms-1900060-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d00/10330652/88bb2cf4fc1f/nihms-1900060-f0001.jpg

相似文献

1
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.连续输注克拉屈滨、大剂量阿糖胞苷和米托蒽醌用于复发/难治性高级别髓系肿瘤的I期研究结果。
Leuk Lymphoma. 2023 May;64(5):1057-1059. doi: 10.1080/10428194.2023.2185087. Epub 2023 Mar 9.
2
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.在复发/难治性急性髓系白血病或其他高级别髓系肿瘤成人患者中，地西他滨进行表观遗传预处理后使用米托蒽醌、依托泊苷和阿糖胞苷：一项1/2期研究
Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30.
3
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.针对复发/难治性急性髓系白血病及其他高级别髓系肿瘤，进行克拉屈滨、大剂量阿糖胞苷、米托蒽醌和粒细胞集落刺激因子联合剂量递增米托蒽醌的I/II期试验。
Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8.
4
Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.单剂量米托蒽醌联合持续输注中剂量阿糖胞苷加依托泊苷治疗难治性或早期复发的急性髓系白血病。
Leuk Res. 2009 Apr;33(4):511-7. doi: 10.1016/j.leukres.2008.08.009. Epub 2008 Sep 25.
5
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy. cladribine 联合再诱导化疗可改善复发/难治性急性髓系白血病患儿的预后。
Cancer Med. 2021 Feb;10(3):956-964. doi: 10.1002/cam4.3681. Epub 2021 Jan 24.
6
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.在新诊断或复发/难治性急性髓系白血病（AML）或其他高级别髓系肿瘤成人患者中，进行地西他滨序贯（“预激”）与同步给药联合克拉屈滨、阿糖胞苷、粒细胞集落刺激因子（G-CSF）和米托蒽醌（CLAG-M）的随机1期研究。
Leuk Lymphoma. 2020 Jul;61(7):1728-1731. doi: 10.1080/10428194.2020.1728754. Epub 2020 Feb 20.
7
Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series.用克拉屈滨、阿糖胞苷、米托蒽醌和粒细胞集落刺激因子治疗高危急性髓系白血病，随后过渡到清髓性异基因造血干细胞移植：病例系列
Transplant Proc. 2018 Jan-Feb;50(1):246-249. doi: 10.1016/j.transproceed.2017.11.019.
8
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study.地西他滨联合大剂量阿糖胞苷和米托蒽醌与大剂量阿糖胞苷和米托蒽醌治疗复发/难治性急性髓系白血病老年患者的比较：ARMADA 2000 期 3 研究。
Future Oncol. 2019 Oct;15(28):3197-3208. doi: 10.2217/fon-2019-0201. Epub 2019 Sep 12.
9
Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.在难治/复发急性髓系白血病中使用氯法拉滨、阿糖胞苷和米托蒽醌：高缓解率和有效桥接异基因造血干细胞移植。
Cancer Med. 2020 May;9(10):3371-3382. doi: 10.1002/cam4.2865. Epub 2020 Mar 18.
10
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.克拉屈滨联合大剂量阿糖胞苷、米托蒽醌和粒细胞集落刺激因子（CLAG-M）是一种治疗预后不良的难治性和复发性急性髓系白血病患者的高效挽救方案：波兰成人白血病组的最终报告
Eur J Haematol. 2008 Feb;80(2):115-26. doi: 10.1111/j.1600-0609.2007.00988.x. Epub 2007 Dec 11.

本文引用的文献

1
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.针对复发/难治性急性髓系白血病及其他高级别髓系肿瘤，进行克拉屈滨、大剂量阿糖胞苷、米托蒽醌和粒细胞集落刺激因子联合剂量递增米托蒽醌的I/II期试验。
Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8.
2
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
3
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.贝叶斯最优区间设计：一种用于I期肿瘤试验的简单且性能良好的设计。
Clin Cancer Res. 2016 Sep 1;22(17):4291-301. doi: 10.1158/1078-0432.CCR-16-0592. Epub 2016 Jul 12.
4
Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.复发或难治性急性髓系白血病成人患者早期死亡的预测
Leuk Lymphoma. 2016 Oct;57(10):2421-4. doi: 10.3109/10428194.2015.1135436. Epub 2016 Jan 11.
5
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.新诊断的急性髓系白血病诱导治疗后早期死亡的预测：一种新的治疗分配范式。
J Clin Oncol. 2011 Nov 20;29(33):4417-23. doi: 10.1200/JCO.2011.35.7525. Epub 2011 Oct 3.
6
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.克拉屈滨联合大剂量阿糖胞苷、米托蒽醌和粒细胞集落刺激因子（CLAG-M）是一种治疗预后不良的难治性和复发性急性髓系白血病患者的高效挽救方案：波兰成人白血病组的最终报告
Eur J Haematol. 2008 Feb;80(2):115-26. doi: 10.1111/j.1600-0609.2007.00988.x. Epub 2007 Dec 11.
7
Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy.正常和白血病白细胞群体的动力学及其与化疗的相关性。
Cancer Res. 1970 Jun;30(6):1883-97.
8
Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.高剂量1-β-D-阿拉伯呋喃糖基胞嘧啶治疗期间白血病细胞中1-β-D-阿拉伯呋喃糖基胞嘧啶5'-三磷酸积累的饱和度
Cancer Res. 1987 Jun 1;47(11):3005-11.